DRMA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DRMA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Dermata Therapeutics's selling, general, & admin. expense for the three months ended in Mar. 2024 was $1.60 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $4.49 Mil.
The historical data trend for Dermata Therapeutics's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermata Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Selling, General, & Admin. Expense | 1.85 | 1.57 | 4.40 | 4.02 | 3.97 |
Dermata Therapeutics Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Selling, General, & Admin. Expense | Get a 7-Day Free Trial | 1.09 | 0.89 | 0.91 | 1.09 | 1.60 |
For the Biotechnology subindustry, Dermata Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Dermata Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Dermata Therapeutics's Selling, General, & Admin. Expense falls into.
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermata Therapeutics (NAS:DRMA) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Thank you for viewing the detailed overview of Dermata Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Brittany Bradrick | director | C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130 |
Gerald T Proehl | 10 percent owner, officer: Pres., CEO and Chairman | |
Van Hoose Kyri K. | officer: Chief Financial Officer | C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Mary Fisher | director | C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532 |
David F Hale | director | 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024 |
Steven J Mento | director | C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804 |
Wendell Wierenga | director | C/O CIPHERGEN BIOSYSTEMS INC, 6611 DUMBARTON CIRCLE, FREMONT CA 94555 |
Kathleen D. Scott | director | C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127 |
Thomas Insley | officer: Chief Financial Officer | SKINMEDICA, INC., 5909 SEA LION PLACE, SUITE H, CARLSBAD CA 92010 |
Bedoya-toro Munera Maria E | officer: Senior VP | 10590 WEST OCEAN AIR DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Andrew Seth Sandler | director | 1301 2ND AVE, SEATTLE WA 98101 |
Christopher J. Nardo | officer: Senior VP, Development | C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130 |
Proehl Investment Ventures Llc | 10 percent owner | C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #332, SAN DIEGO CA 92130 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 06-13-2022
By ACCESSWIRE ACCESSWIRE • 12-05-2022
By ACCESSWIRE ACCESSWIRE • 03-24-2022
By ACCESSWIRE ACCESSWIRE • 04-21-2022
By ACCESSWIRE ACCESSWIRE • 03-28-2022
By ACCESSWIRE • 11-16-2023
By ACCESSWIRE • 08-31-2023
By ACCESSWIRE ACCESSWIRE • 08-16-2022
By ACCESSWIRE • 06-27-2023
By ACCESSWIRE ACCESSWIRE • 02-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.